Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TRI

Carrot Inc. Announces Clinical Trial Outcomes for Pivot, its Evidence-based Digital Health Solution for Smoking Cessation


REDWOOD CITY, Calif., July 17, 2019 /PRNewswire/ -- Digital health company Carrot Inc. today announced the results of the largest clinical trial yet for Pivot®, its smoking cessation program.1 Investigators enrolled 319 people who smoke and assessed Pivot's impact on participant motivation to quit smoking and cigarettes consumed per day. Six out of 7 participants (85.7%) who completed the study indicated that Pivot increased their motivation to quit, and nearly 1 in 3 (32.4%) achieved a successful quit.

Pivot is an evidence-based, mobile, smoking cessation program that includes an FDA-cleared personalized carbon monoxide breath sensor (quantifies smoking behavior), a mobile app, behavioral counseling, pharmacotherapy, community support, motivational lessons, and a clear road map to help people quit smoking.

The trial included US adult participants who reported smoking cigarettes on a daily basis (averaging 18 cigarettes per day for 26 years). At study entry, 2 of 3 participants (66.5%) indicated they were not ready to quit smoking in the next 30 days. This is clinically relevant because these participants achieved similar quit rates as those who were ready to quit in the next 30 days (32.8% in not ready to quit vs. 31.5% in ready to quit), indicating that Pivot can be effective in a broad population of people who smoke, rather than exclusively in those ready to quit.

"Demonstrating a quit rate of 32.4% exceeded our expectations, mainly because so many participants were not ready to quit smoking when they enrolled in the study," said Jennifer D. Marler, M.D., Sr. Director Clinical and Medical Affairs. "Engagement was high in the trial, with 80% of participants making one or more serious quit attempts (one day of abstinence). We were also encouraged to find that in the cohort that did not achieve a quit during the trial, their daily cigarette consumption was reduced by an average of 29.1%. The data indicates that Pivot can increase motivation to quit, reduce cigarette consumption, and lead to a significant quit rate for a broad population of people who smoke, regardless of their readiness to quit."

About Carrot Inc. (carrot.co/
Carrot is a digital health company based in Redwood City, California. 

Related Links: 
https://pivot.co

1  Marler JD, Fujii CA, Utley DS, Tesfamariam LJ, Galanko JA, Patrick H. Initial Assessment of a Comprehensive Digital Smoking Cessation Program That Incorporates a Mobile App, Breath Sensor, and Coaching: Cohort Study. JMIR Mhealth Uhealth. 2019 Feb 4;7(2):e12609. 

 

SOURCE Carrot Inc.


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: